» Articles » PMID: 27583921

Poor Adherence and Low Persistency Rates for Hepatocellular Carcinoma Surveillance in Patients with Chronic Hepatitis B

Overview
Specialty General Medicine
Date 2016 Sep 2
PMID 27583921
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Our goal was to examine rates and predictors for hepatocellular carcinoma (HCC) surveillance adherence and persistency, since studies of such adherence and persistency in patients with chronic hepatitis (CHB) are currently limited.Consecutive CHB patients (N = 1329) monitored for ≥1 year at 4 US clinics from January 1996 to July 2013 were retrospectively studied. Surveillance adherence was evaluated based on the American Association for the Study of Liver Diseases guidelines. Kaplan-Meier method was used to analyze surveillance persistency of 510 patients who had initially fair adherence (having at least annual surveillance imaging with further follow-up).Mean age was 48, with the majority being male (58%), Asian (92%), foreign-born (95%), and medically insured (97%). Patients with cirrhosis and those seen at university liver clinics were more likely to have optimal HCC surveillance than those without cirrhosis and those seen at community clinics (38.4% vs 21.6%, P <0.001 and 33.5% vs 14.4%, P < 0.001, respectively). HCC diagnosed in optimally adherent patients trended toward smaller tumor size (P < 0.08). On multivariate analysis also inclusive of age, sex, clinical visits, cirrhosis, clinic setting and antiviral therapy use, strong independent predictors for having at least annual imaging were a history of more frequent clinical visits (odds ratio [OR] = 2.5, P < 0.001) and university-based care (OR = 5.2, P < 0.001). Even for those with initially fair adherence, persistency dropped to 70% at 5 years.Adherence and persistency to HCC surveillance in CHB patients is generally poor. More frequent clinic visits and university-based settings were significant and strong predictors of at least annual HCC surveillance adherence.

Citing Articles

Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A systematic review of qualitative findings.

Moussa D, Flores J, Doyle J, Ryan M, Wallace J, Howell J PLoS One. 2025; 20(1):e0313216.

PMID: 39792827 PMC: 11723554. DOI: 10.1371/journal.pone.0313216.


Addressing Barriers to Care in Hepatocellular Carcinoma: Promoting Equity and Access.

Vikash S, Vikash F, Sudan A, Adal B, Kotler D Cureus. 2023; 15(7):e41893.

PMID: 37581159 PMC: 10423639. DOI: 10.7759/cureus.41893.


Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.

Huang D, Singal A, Kanwal F, Lampertico P, Buti M, Sirlin C Nat Rev Gastroenterol Hepatol. 2023; 20(12):797-809.

PMID: 37537332 DOI: 10.1038/s41575-023-00818-8.


Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States.

Nguyen M, Roberts L, Engel-Nitz N, Bancroft T, Ozbay A, Singal A Hepatol Commun. 2022; 6(12):3443-3456.

PMID: 36178256 PMC: 9701467. DOI: 10.1002/hep4.2087.


Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B.

Remington T, Osman M, Simmonds K, Charlton C, Doucette K Can Liver J. 2022; 3(3):263-275.

PMID: 35992529 PMC: 9202705. DOI: 10.3138/canlivj.2019-0024.


References
1.
Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm E, Yopp A, Singal A . Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014; 13(4):791-8.e1. PMC: 4289665. DOI: 10.1016/j.cgh.2014.06.031. View

2.
Singal A, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4):e1001624. PMC: 3972088. DOI: 10.1371/journal.pmed.1001624. View

3.
Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

4.
. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

5.
Hamman M, Kapinos K . Affordable Care Act Provision Lowered Out-Of-Pocket Cost And Increased Colonoscopy Rates Among Men In Medicare. Health Aff (Millwood). 2015; 34(12):2069-76. DOI: 10.1377/hlthaff.2015.0571. View